The Prostate Cancer market was impacted by nmCRPC1, mCSPC2 and mCRPC3 data presented during the ASCO Genitourinary Cancers Symposium (ASCO-GU) meeting in San Francisco, CA.
Breaking Data worked with 30 oncologists during the meeting to better understand the commercial implications of data presented for ZYTIGA® (abiraterone), ERLEADA® (apalutamide), XTANDI® (enzalutamide), LYNPARZA® (olaparib) + KEYTRUDA® (pembrolizumab), YERVOY® (ipilimumab) + OPDIVO® (nivolumab), ZEJULA®, (niraparib) and darolutamide.
Companies presenting data included: AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, Merck, Pfizer.
Get immediate access to this 54-slide report so you can make better decisions today and prepare for tomorrow.
Prostate Cancer Report ASCO GU 2019
1. Non-metastatic Castration-resistant Prostate Cancer
2. Metastatic Castration-Sensitive Prostate Cancer
3. Metastatic Castration-resistant Prostate Cancer